AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2015
Jan 6, 2015
29864_dirs_2015-01-06_81138446-fd3c-4b5e-810c-2a3468c3e49c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2015-01-02
Reporting Person: ULLIAN ELAINE (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-01-02 | Common Stock | M | 5000 | $34.32 | Acquired | 10265 | Direct |
| 2015-01-02 | Common Stock | S | 100 | $118.91 | Disposed | 10165 | Direct |
| 2015-01-02 | Common Stock | S | 1700 | $122.15 | Disposed | 8465 | Direct |
| 2015-01-02 | Common Stock | S | 3100 | $122.96 | Disposed | 5365 | Direct |
| 2015-01-02 | Common Stock | S | 100 | $123.57 | Disposed | 5265 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-01-02 | Stock Option (right to buy) | $34.32 | M | 5000 | Disposed | 2016-05-31 | Common Stock (5000) | Direct |
Footnotes
F1: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $122.15 (range $121.53 to $122.48).
F3: Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $122.96 (range $122.54 to $123.41).
F5: Fully vested.